NewAmsterdam Pharma Company N.V.

NAMS

$25.35

-1.95%

2026-09-04 12:21:39 EDT-$0.50

Healthcare

Biotechnology

NASDAQ

Negociación activa

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing ...

Métricas clave de NAMS

Instantánea

Último / TTM · 6 periodos

Capitalización

$3.02B

ROCE

-38.7%

EV / EBITDA

-10.19x

-5.7% YoY

Rendimiento FCF

-4.8%

-1.1% YoY

Ciclo de conversión de efectivo

-2310.3d

Ratio corriente

9.03

Resumen rápido

TTM —

Sin señales de riesgo importantes en las métricas seleccionadas.

Métricas clave

Último / TTM · 6 periodos

Tendencia de valoración

Tendencia de valoración table

Metric	2021	2022	2023	2024	2025	TTM
Market CapTotal market value of all shares outstanding.	$173.07M	$206.73M	$917.73M	$2.43B	$4.01B	$3.02B
Enterprise ValueCompany value including debt and cash adjustments.	$112.88M	$-260.87M	$577.34M	$1.65B	$3.52B	$2.60B
EV / SalesHow many dollars investors pay per dollar of sales.	0.00x	-2.54x	40.97x	36.29x	156.57x	364.82x
EV / EBITDAValuation multiple versus operating earnings before non-cash charges.	-2.73x	11.68x	-3.26x	-6.85x	-14.54x	-10.19x
Net Debt / EBITDALeverage ratio using net debt divided by EBITDA.	1.46	20.93	1.92	3.19	2.02	1.66

Retornos + indicador ROCE

ROCE más reciente

-38.7%

Prev year -33.0%

Retornos + indicador ROCE table

Metric	2021	2022	2023	2024	2025	TTM
ROEProfit generated from shareholders' equity.	-73.8%	-5.3%	-61.4%	-31.9%	-29.8%	-38.3%
ROAProfit generated from total assets.	-61.5%	-4.7%	-51.0%	-27.9%	-26.5%	-36.8%
ROICReturn generated on invested operating capital.	-74.0%	-5.1%	-59.5%	-31.9%	-41.0%	-43.5%
ROCEOperating return on long-term capital used.	-61.6%	-0.8%	-61.6%	-23.3%	-33.0%	-38.7%
Earnings YieldEarnings as a percentage of market value.	-24.1%	-10.9%	-19.3%	-10.0%	-5.1%	-8.1%

Calidad del flujo de caja

Calidad del flujo de caja table

Metric	2021	2022	2023	2024	2025	TTM
FCFFCash flow available to all capital providers.	$-29.13M	$10.73M	$-134.44M	$-159.24M	$-148.03M	$-143.72M
FCFECash flow available to equity holders after debt flows.	$-29.54M	$11.19M	$-141.24M	$-159.24M	$-148.03M	$-143.72M
FCF YieldFree cash flow divided by market capitalization.	-17.1%	5.1%	-15.4%	-6.6%	-3.7%	-4.8%
Income QualityHow well accounting earnings are backed by cash flow.	0.71	-0.47	0.80	0.66	0.73	0.97
Capex / OCFShare of operating cash flow spent on capital expenditures.	-0.1%	2.1%	-0.0%	-0.4%	-0.2%	-0.2%

Eficiencia operativa

Eficiencia operativa table

Metric	2021	2022	2023	2024	2025	TTM
DSOAverage days to collect cash from customers.	0.0d	0.0d	48.7d	170.7d	375.5d	1230.0d
DIOAverage days inventory stays before being sold.	0.0d	0.0d	0.0d	0.0d	0.0d	0.0d
DPOAverage days the company takes to pay suppliers.	0.0d	0.0d	0.0d	0.0d	55492.4d	3540.3d
Operating CycleTime from buying inventory to collecting receivables.	0.0d	0.0d	48.7d	170.7d	375.5d	1230.0d
Cash Conversion CycleNet days cash is tied in operations.	0.0d	0.0d	48.7d	170.7d	-55116.8d	-2310.3d

Instantánea

Último / TTM: —

Capitalización

$3.02B

ROE

-38.3%

Rendimiento FCF

-4.8%

Ratio corriente

9.03

Upstream

Piramal Pharma Solutions (Piramal Pharma Ltd)NSE:PPLPHARMAUnnamed CDMO (Canada-based)Unnamed CDMO (Austria-based)Unnamed CDMO (US-based, not Piramal)API Raw Material Suppliers (via Piramal Pharma Solutions network)Ezetimibe API Suppliers (generic drug substance)

Downstream

A. Menarini International Licensing S.A. (Menarini Group)Menarini Group (EU Distribution Network)US Market (Direct Commercialization – Planned)Japan Partner (Phase 2 Study Initiated)

Empresas proxy

Piramal Pharma LtdNSE:PPLPHARMAAmgen Inc.NASDAQ:AMGN Esperion Therapeutics Inc.NASDAQ:ESPR Novartis AGNYSE:NVS

Sobre nosotrosPolítica de privacidadTérminos de servicioAviso legalDirectorio de accionesETFÍndicesCarteras 13FPrecios objetivoHerramientas gratuitasMapa tecnológicoÚnete a nuestro Slack

Plutux no es un asesor de inversiones. Los datos de mercado y el análisis generado por IA son solo informativos y educativos, no asesoramiento de inversión. Aviso legal

No se encontraron acciones que coincidan

NewAmsterdam Pharma Company N.V.

Métricas clave de NAMS

Métricas clave

Tendencia de valoración

Retornos + indicador ROCE

Calidad del flujo de caja

Eficiencia operativa

Instantánea

Cadena de suministro de NAMS

Upstream

Downstream

Empresas proxy

Métricas clave de NAMS

Métricas clave

Tendencia de valoración

Retornos + indicador ROCE

Calidad del flujo de caja

Eficiencia operativa

Instantánea

Cadena de suministro de NAMS

Upstream

Downstream

Empresas proxy